Company intelligence / Profile preview
InterveXion Therapeutics
Little Rock, Arkansas, United States
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
InterveXion Therapeutics has reported positive Phase 2 data for its lead monoclonal antibody program, IXT-m200, in both methamphetamine use disorder and acute overdose. The STAMPOUT study demonstrated proof-of-concept efficacy. Additional Phase 2 studies—OUTLAST for MUD and MethOD for overdose—are ongoing or recently completed with positive safety/tolerability results. Devextinetug also showed safety and normalization of agitation in METH overdose patients in a separate Phase 2 trial.
- Therapeutic areas
- Psychiatry
- Modalities
- Monoclonal antibodies (mAbs)ImmunotherapiesVaccines (in development)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) – major grant funding partnerUniversity of Arkansas for Medical Sciences – academic collaboration/sub-awardee
Beyond the preview
Go deeper on InterveXion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterveXion Therapeutics.